PEA0062 Epigenetic silencing siRNA delivered to the nucleus of HIV-1 infected cells via nanoparticle systemE-posterA20
OAA0203 Infection outcome in RT-SHIV infected macaques treated early with antiretroviral therapy alone or in combination with the TLR7 agonist vesatolimodOral abstract session with live Q&AA21
OAA0204 Tyrosine kinase inhibitors promote antiviral resistance in CD4+ T cells against HIV-1 infection even after treatment withdrawalOral abstract session with live Q&AA21
PEA0063 Dual bromodomain-histone deacetylase inhibitors designed as latency-reversing agentsE-posterA21
PEA0064 Chronic HIV-1 patients on treatment with tyrosine kinase inhibitors have a low reservoir size and active cytotoxic cell populationsE-posterA21
LBPEA01 Long-acting starch nanoparticle drug delivery system to treat chronic HIVE-posterA22
LBPEA03 Vpu inhibitor BIT225 alters T cell activation and homing plasma membrane receptor expression on CD4+T cells (CD28 and CCR7) and monocyte-derived macrophages (CD80 and CD86)E-posterA22
PEA0065 Alternative 'morning after' rectal or vaginal administration approach for post-exposure prophylaxis of HIVE-posterA22
PEA0066 A pilot study: CRISPR/Cas9 therapy for an effective control of genetically diverse HIV-1E-posterA23
OAALB0103 CCR5 antibody blockade protects rhesus macaques from rectal SHIV acquisitionOral abstract session with live Q&AA24
seek-warrow-warrow-eseek-e51 - 60 of 2297 items